ID Genomics Inc - also listed as ID Genomics SPC - is a clinical-stage biotechnology company developing in vitro diagnostics to guide antibiotic treatments for urinary tract infections (UTIs). The firm is addressing combating antibiotic resistance by combining epidemiological big data with precision diagnostics using a process that mitigates patient risk and generates favorable outcome. Researchers with IDG have identified CLoNeT, a set of unique bacterial barcodes that quickly identify resistant bacteria in patient samples. First-generation CLoNeT tests target urinary tract infections, which are at the forefront of the drug resistance crisis. The firm's big data platform, BactNeT, links bacterial samples, IDG's proprietary barcodes, and clinical information with responses to commonly prescribed antibiotics. Insight. Together with CLoNeT, BactNeT forms a state-of-the art epidemiological surveillance network that has the potential to provide transformative solutions and bring the appropriate medicine directly to the patients bedside. Urgent-care clinical trials show that te firm's first generation diagnostic for UTIs, CLoNeT, yields results in less than 45 minutes, and reduces the rate of antibiotic prescription errors from 25% to less than 3%.
